12.02
-0.14 (-1.11%)
| Previous Close | 12.15 |
| Open | 12.16 |
| Volume | 1,890,462 |
| Avg. Volume (3M) | 5,731,088 |
| Market Cap | 8,746,319,872 |
| Price / Earnings (TTM) | 2.17 |
| Price / Sales | 76.51 |
| Price / Book | 1.71 |
| 52 Weeks Range | |
| Earnings Date | 11 Feb 2025 - 17 Feb 2025 |
| Profit Margin | 3,725.10% |
| Operating Margin (TTM) | -7,446.10% |
| Diluted EPS (TTM) | 5.54 |
| Quarterly Revenue Growth (YOY) | 22.70% |
| Total Debt/Equity (MRQ) | 0.94% |
| Current Ratio (MRQ) | 10.43 |
| Operating Cash Flow (TTM) | -778.54 M |
| Levered Free Cash Flow (TTM) | -472.58 M |
| Return on Assets (TTM) | -18.44% |
| Return on Equity (TTM) | 128.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Roivant Sciences Ltd. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.5 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 0.5 |
| Average | 0.63 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 28.92% |
| % Held by Institutions | 79.48% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sb Investment Advisers (Uk) Ltd | 30 Sep 2024 | 65,934,074 |
| Qvt Financial Lp | 30 Sep 2024 | 65,793,779 |
| Patient Square Capital Lp | 30 Sep 2024 | 12,228,465 |
| 52 Weeks Range | ||
| Median | 18.00 (49.81%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 13 Nov 2024 | 18.00 (49.81%) | Buy | 11.95 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |